Introduction
============

Borderline personality disorder (BPD) is characterized by affective instability, emotion dysregulation, and poor interpersonal functioning ([@R10]). BPD has a prevalence of 1--2%, and is associated with major psychosocial dysfunction and economic burden ([@R10]).

At the time of writing, the etiology of BPD remains unclear ([@R10]). Heritability estimates from family and twin studies range between 35 and 65% ([@R19]; [@R5]). To date, genetic research into BPD has been limited. Previous genetic studies of BPD involved small samples, and focused on candidate genes, for example from the serotonergic system (*SLC6A4*, *TPH2*, *MAOA*); the dopaminergic system (*COMT*, *MAOA*); and the neurotrophins (*BDNF*) ([@R2]). The results of these studies have been inconsistent. In contrast to other major psychiatric disorders, no genome-wide significant studies for BPD have been reported as yet.

An interesting feature of BPD in terms of the hunt for genetic factors is the high level of psychiatric comorbidity. In particular, individuals with BPD show high comorbidity, and a considerable overlap in terms of phenomenology, with bipolar disorder (BD) ([@R20]). Both BPD and BD are characterized by a tendency toward impulsivity, affective instability, recurrent suicidality, intense anger, and unstable interpersonal relationships. Thus, previous authors have challenged the BPD/BD dichotomy, and hypothesized that these two disorders may in fact have a common etiology ([@R1]). The nosological relationship between these two major psychiatric disorders is the subject of intense ongoing debate within the field ([@R3]).

The phenomenological overlap and the high comorbidity between BD and BPD suggest the hypothesis of a common genetic background. This in turn suggests that investigation of genetic risk variants for BD in BPD samples is warranted. So far, no twin or family studies have provided conclusive results on whether there is a genetic overlap between the two disorders ([@R13]; [@R16]).

The aim of the present study was to investigate genome-wide significant variants for BD located in the genes *CACNA1C*, *ANK3*, and *ODZ4* ([@R6]; [@R17]) in well-characterized BPD case--control samples to determine the existence of a common genetic background.

Materials and methods
=====================

Participants
------------

The present analyses involved 673 BPD patients and 748 controls (for details of recruitment sites and clinical assessment, see SDI, Supplemental digital content 1, [*http://links.lww.com/PG/A115*](http://links.lww.com/PG/A115)). Written informed consent was obtained from all participants before inclusion. All study procedures conformed to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 6th revision, 2008). The study was approved by the ethics committees of each study center. Demographic data for the patients and the controls are shown in Table S1a/b (SDI, Supplemental digital content 1, [*http://links.lww.com/PG/A115*](http://links.lww.com/PG/A115)).

SNP selection
-------------

The genetic variants of interest were five genome-wide significant risk variants identified for BD: rs1006737 \[*P*=7.0×10^--8^, ([@R6])\] \[*P*=3.1×10^--8^, ([@R12])\] and rs4765913 \[*P*=1.52×10^--8^, (Psychiatric GWAS Consortium Bipolar Disorder Working Group, 2011)\] in *CACNA1C*; rs10994336 \[*P*=9.1×10^--9^, ([@R6])\] and rs10994397 \[*P*=7.08×10^--9^, ([@R17])\] in *ANK3*; and rs12576775 \[*P*=4.40×10^--8^, ([@R17])\] in *ODZ4*.

Genotyping
----------

Genomic DNA was prepared from whole blood according to standard procedures. Selected single-nucleotide polymorphisms (SNPs) were genotyped using the iPLEX assay on the MassARRAY MALDI-TOF mass spectrometer (SEQUENOM, San Diego, California, USA) within the context of a larger study. For details, see SDI (Supplemental digital content 1, [*http://links.lww.com/PG/A115*](http://links.lww.com/PG/A115)).

Statistical analysis
--------------------

Data preparation and analysis were carried out using the following three software packages: PLINK, version 1.07 ([*http://pngu.mgh.harvard.edu/\~purcell/plink/*](http://pngu.mgh.harvard.edu/~purcell/plink/)); PASW Statistics for Windows, version 18.0. (SPSS Inc., Chicago, Illinois, USA); and R, version 2.15.3 ([*http://www.R-project.org*](http://www.R-project.org)). Associations between genetic markers and phenotypes were tested using the Cochran--Armitage trend test.

Results
=======

Rs1006737 in *CACNA1C* showed a nominally significant association with BPD in the total sample (*P*=0.0498). However, this result did not withstand correction for multiple testing (for details, see Table [1](#T1){ref-type="table"}). Sex-specific analysis showed that this result was driven by an association in the female subsample (*P*=0.01). No association was observed between rs1006737 and BPD in the male subsample (*P*=0.39) (see SDI, Table S2a and S2b, Supplemental digital content 1, [*http://links.lww.com/PG/A115*](http://links.lww.com/PG/A115)). For the remaining four SNPs of interest, no significant association with BPD was observed.
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Allele frequencies and association results for all five SNPs investigated
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Discussion
==========

To investigate the hypothesis that BPD and BD share genetic variation, the present case--control study investigated whether five genome-wide significant risk variants identified for BD were associated with BPD. The analyses identified a nominally significant association between BPD and rs1006737 in *CACNA1C* (*P*=0.0498). In both disorders, the risk of disease was conferred by the A allele. No association with BPD was observed for the remaining four variants (Table [1](#T1){ref-type="table"}). Sex-specific analysis of the SNPs showed that the rs1006737 signal was present in women (*P*=0.01), but not in men (*P*=0.39). A further SNP in *CACNA1C* (rs4765913) showed a significant association only in women (*P*=0.01) (Table S2a/b SDI, Supplemental digital content 1, [*http://links.lww.com/PG/A115*](http://links.lww.com/PG/A115)). However, this variant is in high linkage disequilibrium with rs1006737 (*D*′=0.9), and thus this cannot be considered an independent finding.

Interestingly, previous studies have identified sex-specific associations between *CACNA1C* and BD. In particular, an association study of a combined BD and major depression dataset in 3,800 patients reported an association with the A allele of rs1006737 only in women (*P*=0.025) ([@R4]). Furthermore, sex-specific effects were found for personality traits ([@R18]). Here, however, higher emotional lability and lower resilience were associated with the A allele in men and the G alleles in women, respectively ([@R18]). This seemingly reversed allele effect is a well-known phenomenon encountered in other complex disorders as well ([@R11]). For a detailed discussion on this topic, see the study by [@R18].

Besides BD, *CACNA1C* has also been associated with major depression and schizophrenia ([@R7]; [@R12]). This suggests that *CACNA1C* plays a general role in the pathomechanisms that underlie psychiatric disease. Imaging genetic studies have shown that rs1006737 also exerts pleiotropic effects on particular brain functions, such as the regulation of emotion and memory and attention networks, and that it affects different brain regions, including the amygdala, the hippocampus, and the ventrolateral prefrontal cortex. Alterations in these brain functions and regions have also been found in BPD, and several authors have proposed these alterations as pathogenetic models for BPD ([@R14]; [@R8]; [@R15]).

The present finding must be considered preliminary as it was only nominally significant and did not withstand correction for multiple testing. Furthermore, although our cohort represented the largest BPD cohort in published genetic studies to date, the sample size was limited compared with that required for successful association studies of other complex disorders (Visscher *et al.* 2012).

Novel statistical approaches now allow the analysis of an overlap in common genetic variation between diagnostic categories, and this approach has already been used for other major psychiatric diseases. For example, a meta-analysis of GWAS data for five psychiatric disorders showed a large genetic overlap ([@R9]). A plausible assumption therefore is that future studies of the GWAS data of large samples of BPD patients will provide further insights into its etiology and the genetic overlap between BPD and BD.

Conclusion
----------

This is the first report of an association between a BD risk gene and BPD where selection was not based on *a priori* hypotheses about its function, but on an unbiased hypothesis-free screening of the genome. Genome-wide association data of large samples of BPD are warranted and will eventually identify new risk genes and the overlap between BPD and BD if it exists.
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